This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Permax

Valeant Pharmaceuticals International, Inc.

Drug Names(s): pergolide mesylate

Description: Permax (Pergolide Mesylate) is an ergot derivative dopamine receptor agonist at both D1 and D2 receptor sites. Pergolide mesylate inhibits the secretion of prolactin in humans; it causes a transient rise in serum concentrations of growth hormone and a decrease in serum concentrations of luteinizing hormone. In Parkinson’s disease, pergolide mesylate is believed to exert its therapeutic effect by directly stimulating postsynaptic dopamine receptors in the nigrostriatal system.

Deal Structure: Permax was launched by Eli Lilly in the U.S. in 1988 and acquired by lan from Eli Lilly and Company in 1993.

In July 2001, Amarin announced that it has entered into a strategic partnership with lan. Under terms of the agreement, Amarin gains exclusive U.S. marketing, sales and distribution rights to Permax tablets. As part of the agreement, Amarin has also received an option to acquire Permax in the U.S. from lan.

In Feb 2004, Valeant acquired the US rights to Permax from Amarin Corporation.

Partners: Eli Lilly & Company


Permax News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug